Do not administer by IV. Inj into a lifted skin fold to minimise risk of unintended IM inj. Do not use in insulin infusion pumps. Inj site reactions may occur. Always rotate inj sites w/in the same region. Blood glucose monitoring is recommended after change in the inj site from an affected to an unaffected area, & dose adjustment of antidiabetic medications may be considered. Close glucose monitoring is recommended when transferring from other insulin medicinal products (change in strength, brand, type, origin &/or method of manufacture) & in the initial wk thereafter. Dose adjustment may be necessary if patients undertake increased physical activity, change their usual diet, or during concomitant illness (especially infections & feverish conditions; concomitant diseases in the kidney, liver or affecting the adrenal, pituitary or thyroid gland). Risk of hyperglycaemia & diabetic ketoacidosis w/ inadequate dosing or treatment discontinuation, especially in type 1 diabetes. Risk of hypoglycaemia w/ excessive insulin dose, omitted meal, or unplanned, strenuous physical exercise. Do not inj in case of hypoglycaemia or if hypoglycaemia is suspected. Change in usual warning symptoms of hypoglycaemia in patients w/ greatly improved blood glucose control (eg, by intensified insulin therapy); disappearance of usual warning symptoms in patients w/ longstanding diabetes. Reports of cardiac failure when used in combination w/ pioglitazone, especially in patients w/ risk factors for development of cardiac heart failure. May impair ability to drive or operate machinery. Intensify glucose monitoring & adjust insulin dose on an individual basis in patients w/ renal or hepatic impairment, & the elderly. Pregnancy & lactation. Patients travelling between different time zones.
Sign Out
